Pembrolizumab: A reliable second‐line treatment option for advanced esophageal cancer

Detalles Bibliográficos
Autores principales: Zheng, Li, Zhu, Yabi, Liu, Yangyang, Ma, Xu, Xu, Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013639/
https://www.ncbi.nlm.nih.gov/pubmed/35307966
http://dx.doi.org/10.1111/1759-7714.14395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013639/
https://www.ncbi.nlm.nih.gov/pubmed/35307966
http://dx.doi.org/10.1111/1759-7714.14395

Ejemplares similares